Status:
ACTIVE_NOT_RECRUITING
A Study of Ninlaro in Real World Clinical Practice in China
Lead Sponsor:
Takeda
Conditions:
Multiple Myeloma
Neoplasms, Plasma Cell
Eligibility:
All Genders
18+ years
Brief Summary
The main purpose of this study is to collect additional safety information of ixazomib citrate (Ninlaro) when used to treat multiple myeloma in real world clinical practice in China. Participants will...
Detailed Description
This is a prospective, non-interventional study in Chinese participants with relapsed refractory multiple myeloma (RRMM), newly diagnosed multiple myeloma (NDMM) and non-myeloma who are undergoing or ...
Eligibility Criteria
Inclusion
- Undergoing treatment with Ninlaro (of less than 3 months from initial treatment with Ninlaro) or to be prescribed with Ninlaro capsule.
- Participants will be able to sign Informed Consent Form to participate.
Exclusion
- Currently participates or plans to participate in any interventional clinical trial.
- Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.
Key Trial Info
Start Date :
May 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2026
Estimated Enrollment :
482 Patients enrolled
Trial Details
Trial ID
NCT04328662
Start Date
May 18 2020
End Date
March 30 2026
Last Update
April 10 2025
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Cancer Hospital
Hefei, Anhui, China, 230031
2
Beijing Chao-yang Hospital,Capital Medical University
Beijing, Beijing Municipality, China, 100020
3
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
4
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China, 100035